Skyrizi cleared for pediatric psoriatic disease

Sponsor

AbbVie $ABBV

Drug

Skyrizi · risankizumab-rzaa

Indication

Moderate-to-severe plaque psoriasis and active psoriatic arthritis in patients aged 6 and older

FDA approved Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, expanding its existing adult indications into the pediatric age group.